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PURPOSE To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with
cancer and hematopoietic stem-cell transplantation (HSCT) recipients.
METHODS Recommendations were developed by an international multidisciplinary panel that included a patient
advocate. We conducted a systematic review of systemic antifungal prophylaxis in children and adults with
cancer and HSCT recipients. The Grading of Recommendations Assessment, Development, and Evaluation
approach was used to make strong or weak recommendations and to classify level of evidence as high,
moderate, low, or very low. The panel considered directness of the data to pediatric patients.
RESULTS There were 68 randomized trials included in the systematic review, of which 6 (9%) were conducted in
a solely pediatric population. Strong recommendations were made to administer systemic antifungal prophylaxis
to children and adolescents receiving treatment of acute myeloid leukemia, to those undergoing allogeneic
HSCT pre-engraftment, and to those receiving systemic immunosuppression for graft-versus-host disease
treatment. A strong recommendation was made to administer a mold-active agent with an echinocandin or
a mold-active azole when systemic antifungal prophylaxis is warranted. For children younger than 13 years of
age, an echinocandin, voriconazole, or itraconazole is suggested. Posaconazole may also be used in those age
13 years or older. A strong recommendation against routine administration of amphotericin as systemic an-
tifungal prophylaxis was made.
CONCLUSION We developed a clinical practice guideline for systemic antifungal prophylaxis administration in
pediatric patients with cancer and HSCT recipients. Implementation and assessment of guideline-concordant
rates and impacts are important future steps.
J Clin Oncol 38. © 2020 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
INTRODUCTION
Children and adolescents receiving intensive myelo-
suppressive chemotherapy and some pediatric hema-
topoietic stem-cell transplantation (HSCT) recipients are
at high risk for invasive fungal disease (IFD) caused by
yeasts and molds.1-4 In these patients, infections with
Candida and Aspergillus species are most common.1-3
IFDs are important because they are associated with
substantial morbidity, delayed cancer treatment,
increased health services utilization, and treatment-
related mortality.5
Systemic antifungal prophylaxis can be an effective
approach to reducing IFD. A clinical practice guideline
(CPG) facilitates evidence-based clinical care by de-
scribing risks and benefits of different management
options based on a systematic review of the literature.
Risks and benefits are weighed against each other by
a panel of experts to arrive at care recommendations.
Previously published CPGs6,7 addressing systemic
antifungal prophylaxis in pediatric patients are . 5
years old and thus do not consider results of recent
trials. In addition, those panels had limited regional
and disease representation. Key representatives of two
previously published CPGs for pediatric patients (T.L.,
E.C., L.L.D., A.H.G., E.R., M.S., A.W., P.D.R., and L.S.)6,7
were brought together to arrive at a single harmonized
CPG, thus improving consistency of recommendations
internationally. The objective was to develop a CPG for
systemic antifungal prophylaxis in pediatric patients with
cancer and HSCT recipients.
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METHODS
Panel Constitution
The panel included representatives from the fields of pe-
diatric hematology/oncology, pediatric HSCT, pediatric in-
fectious diseases, nursing, and pharmacy; a patient advocate;
and a CPG methodologist (Data Supplement). Panel mem-
bers were selected based on clinical and methodologic ex-
pertise and geographic representation. All panel members
declared potential conflicts of interest, and none precluded
participation in this CPG (Data Supplement).
General CPG Development Approach
We used standard approaches to create this CPG,8 in-
cluding the Appraisal of Guidelines for Research and
Evaluation II instrument, to direct development.9 Financial
support for CPG creation was provided by the Pediatric
Oncology Group of Ontario. However, CPG development,
drafting of recommendations and the manuscript, and the
decision to submit for publication were independent from
the funder.
The key clinical questions were developed by the panel and
are listed in Table 1. The target population is children and
adolescents (age 0-18 years) receiving chemotherapy for
cancer or undergoing HSCT. Target users are physicians,
microbiologists, nurse practitioners, nurses, pharmacists,
antibiotic stewards, and other health care professionals
who are concerned with infectious complications in pedi-
atric patients receiving chemotherapy or undergoing HSCT.
Panel members identified and rated the importance of
outcomes by consensus. Outcomes that were considered
critical for decision making were proven or probable IFD,
mold infection or yeast infection, fungal infection–related
mortality, and overall mortality. Outcomes considered im-
portant were drug-related adverse effects and antifungal
resistance. Empirical antifungal therapy was not considered
important and, thus, not evaluated. Because changing di-
agnostic technologies can influence possible IFD events,
possible IFD was included post hoc as an outcome.
To rate the level of evidence and to formulate recom-
mendations, the Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) approach
was used.10 The level of evidence indicates the degree of
certainty that estimates from the systematic review reflect
effects of prophylaxis in our target population, namely
pediatric patients with cancer and HSCT recipients. Evi-
dence was rated as high, moderate, low, or very low. Rating
was downgraded if there were limitations in study design,
lack of consistency, or imprecision or if direct data were
lacking. Considering the level of evidence, strong or weak
recommendations were made. Strong recommendations
were made where benefits clearly outweighed the risks or
vice versa and, thus, patients should receive or not receive
the intervention as a general policy. Weak recommenda-
tions were made where the benefits and risks were closely
matched or where there was uncertainty in their estimates.
Efficacy, toxicity, and resources, including costs, influ-
enced recommendation formulation.
Searching, Selecting, and Describing the Evidence
The evidence base used to create this CPG was founded on
randomized clinical trials because they are generally less
susceptible to bias in comparison with observational tri-
als.11 The literature search was performed with the assis-
tance of a library scientist in the following databases:
MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of
Print, and Embase. The Data Supplement shows the full
search strategy. Inclusion criteria were fully published
randomized trials with a parallel group design that com-
pared the administration of a systemic antifungal agent to
any control group as prophylaxis. At least 90% of study
participants had to be patients with cancer receiving
CONTEXT
Key Objectives
Which pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients should routinely receive
systemic antifungal prophylaxis?
Knowledge Generated
Based on a systematic review, an international multidisciplinary guideline panel recommended systemic antifungal
prophylaxis be administered to children and adolescents receiving treatment of acute myeloid leukemia, to those
undergoing allogeneic HSCT pre-engraftment, and to those receiving systemic immunosuppression for graft-versus-host
disease treatment. When systemic antifungal prophylaxis is warranted, an echinocandin or a mold-active azole should
be used.
Relevance
This clinical practice guideline for systemic antifungal prophylaxis is important because of the impact of invasive fungal
disease in pediatric patients with cancer and HSCT recipients and because of the presence of multiple approaches to
invasive fungal disease prophylaxis, including no prophylaxis.
2 © 2020 by American Society of Clinical Oncology
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TABLE 1. Summary of Recommendations for Systemic Antifungal Prophylaxis in Children and Adolescents With Cancer and Pediatric HSCT Recipients
Health Questions and Recommendations
Strength of Recommendation and Level of
Evidence
Which pediatric patients with cancer and HSCT recipients should routinely receive systemic antifungal
prophylaxis?
Acute myeloid leukemia
1. Administer systemic antifungal prophylaxis to children and adolescents receiving treatment of acute
myeloid leukemia that is expected to result in profound and prolonged neutropenia.
Strong recommendation; high-quality
evidence
Remarks: This strong recommendation is based on the increasing benefit of systemic antifungal
prophylaxis versus no prophylaxis to reduce proven or probable IFD as the risk for IFD increases.
Although this recommendation advocates for a universal prophylaxis approach, future research
should identify patient and treatment factors that may allow tailoring of prophylaxis to those at the
highest risk for IFD.
Acute lymphoblastic leukemia
2. Consider administering systemic antifungal prophylaxis to children and adolescents with newly
diagnosed and relapsed acute lymphoblastic leukemia at high risk for IFD.
Weak recommendation; low-quality
evidence
Remarks: Children and adolescents with acute lymphoblastic leukemia encompass a group with wide
variability in IFD risk that is not solely accounted for by relapse status. Those with relapsed acute
lymphoblastic leukemia receiving intensive myelosuppressive chemotherapy aremost likely to warrant
systemic antifungal prophylaxis, whereas greater uncertainty is present for those with newly diagnosed
acute lymphoblastic leukemia. Given the heterogeneity in IFD risk across protocols overall and by
phase of treatment, adaptation will be required for each protocol to recommend whether and when
systemic antifungal prophylaxis should be administered.
3. Do not routinely administer systemic antifungal prophylaxis to children and adolescents with acute
lymphoblastic leukemia at low risk for IFD.
Strong recommendation; low-quality
evidence
Remarks: A low risk for IFD can be inferred based on absence of risk factors such as prolonged
neutropenia and corticosteroid administration and observed IFD rates across different protocols. This
group includes, for example, pediatric patients receiving maintenance chemotherapy for acute
lymphoblastic leukemia.
Other malignancies including most patients with lymphomas and solid tumors
4. Do not routinely administer systemic antifungal prophylaxis to children and adolescents with cancer at
low risk for IFD, such as most pediatric patients with lymphomas and solid tumors.
Strong recommendation; moderate-
quality evidence
Remarks: In pediatric patients at low risk for IFD, the benefit of systemic antifungal prophylaxis is likely to
be small and outweighed by the risk for adverse effects, costs, and inconvenience. Thus, systemic
antifungal prophylaxis should not routinely be administered in this setting.
HSCT
5. Administer systemic antifungal prophylaxis to children and adolescents undergoing allogeneic HSCT
pre-engraftment and to those receiving systemic immunosuppression for the treatment of graft-versus-
host disease.
Strong recommendation; moderate-
quality evidence
Remarks: The panel recognized that these two phases of therapy are associated with different
epidemiology of IFD. However, the nature of the trials included in the systematic review precluded the
ability to make separate recommendations for them. This strong recommendation was influenced by
the finding in the systemic prophylaxis versus no systemic prophylaxis stratified analysis that HSCT
recipients experienced greater benefit in IFD reduction compared with chemotherapy recipients. In
addition, the subgroup analysis showed that among the HSCT stratum, prophylaxis significantly
reduced fungal infection–related mortality.
6. We suggest that systemic antifungal prophylaxis not be used routinely in children and adolescents
undergoing autologous HSCT.
Weak recommendation; low-quality
evidence
Remarks: This weak recommendation was based on the lower risk for IFD associated with autologous
HSCT. There is less certainty in the setting of tandem transplantations where the cumulative duration
of neutropenia may be longer.
If systemic antifungal prophylaxis is planned, which agents should be used?
7. If systemic antifungal prophylaxis is warranted, administer a mold-active agent. Strong recommendation; high-quality
evidence
(continued on following page)
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chemotherapy or HSCT recipients. There was no restriction
by language. We excluded studies of ketoconazole because
both the US Food and Drug Administration and the Eu-
ropeanMedicines Agency have warned against its systemic
use as a result of the risk for hepatic toxicities, adrenal
suppression, and drug interactions.12,13 The search in-
cluded studies published from January 1, 1980, to No-
vember 18, 2019.
The primary outcome of the systematic review was proven
or probable IFD. Other outcomes were proven or probable
mold infection, proven or probable invasive aspergillosis
(IA), proven or probable yeast infection, overall mortality,
fungal infection–related mortality, and discontinuation of
antifungal prophylaxis as a result of an adverse effect. For
all IFD outcomes (namely IFD, mold infection, IA, and yeast
infection), if the study used the European Organisation for
Research and Treatment in Cancer (EORTC)/Mycosis Study
Group criteria for categorization, proven or probable IFD
outcomes were abstracted. If a study did not use the EORTC
criteria, IFD outcomes were mapped to EORTC categories
(2008 revised version)14 by four investigators (T.L., P.P.,
P.D.R., and L.S.) by consensus where possible. These out-
comes were considered missing if mapping was not possible.
We compared systemic antifungal prophylaxis, mold-active
prophylaxis, and non–mold-active prophylaxis (flucona-
zole) versus no systemic prophylaxis, both by group and
then stratified by specific agent evaluated. We next com-
pared different systemic antifungal prophylaxis agents fo-
cusing on mold-active agents (amphotericin, mold-active
azole, or echinocandin) versus fluconazole as a group and
then broken down by subcategories and specific agents.
We also compared mold-active azole versus echinocandin.
Study and demographic characteristics were year of
publication, country of study conduct, age of participants,
cancer diagnosis or HSCT type, and number of randomly
assigned participants. Study-level covariates were partici-
pant age group (adult, pediatric, or both), treatment group
(chemotherapy only, HSCT only, or both chemotherapy and
HSCT), and EORTC criteria use to classify IFD (yes or no).
Age group was categorized as adult when all participants
were older than 15 years of age, and it was categorized as
pediatric when all participants were younger than 25 years
of age or when the median or mean age was younger than
15 years. Agent dose and schedule, start and stop criteria,
and use of therapeutic drug monitoring were also collected.
The Cochrane Collaboration’s tool for assessing risk of bias
in randomized trials was used.15
Titles and abstracts of articles identified by the systematic
review were screened, and articles potentially meeting el-
igibility criteria were evaluated at full text. All steps, in-
cluding screening, full text review, and data abstraction,
were performed in duplicate (V.F., P.P., or P.D.R.). If
TABLE 1. Summary of Recommendations for Systemic Antifungal Prophylaxis in Children and Adolescents With Cancer and Pediatric HSCT Recipients
(continued)
Health Questions and Recommendations
Strength of Recommendation and Level of
Evidence
Remarks: This strong recommendation was based on the comparison of different systemic antifungal
prophylaxis agents where mold-active agent versus fluconazole significantly reduced proven or
probable IFD, mold infection, and IA, and reduced fungal infection–related mortality. Direct pediatric
data were available, increasing quality of the evidence.
8. In choosing a mold-active agent, administer an echinocandin or a mold-active azole. Strong recommendation; moderate-
quality evidence
Remarks: The choice of specific mold-active agent is influenced by multiple factors including local
epidemiology, adverse effect profile, potential for drug interactions, costs, and jurisdictional
availability. For children younger than 13 years of age, an echinocandin, voriconazole, or itraconazole
is suggested based on efficacy and adverse effects. In those 13 years of age and older, posaconazole
also is an option.
9. Do not use amphotericin routinely as systemic antifungal prophylaxis. Strong recommendation; low-quality
evidence
Remarks: This strong recommendation was based on the finding that both conventional and lipid
formulations of amphotericin were not more effective than fluconazole in reducing IFD. It is important
to note that liposomal amphotericin was not included in studies comparing amphotericin versus
fluconazole and, thus, there is less certainty about the benefits and risks of this formulation.
When should systemic antifungal prophylaxis be started and stopped?
10. If systemic antifungal prophylaxis is warranted, consider administration during periods of observed or
expected severe neutropenia. For allogeneic HSCT recipients, consider administration during
systemic immunosuppression for graft-versus-host disease treatment.
Weak recommendation; low-quality
evidence
Remarks: There are limited data that inform the decision of when to initiate and discontinue systemic
antifungal prophylaxis. This recommendation was based on the criteria used in the included
randomized trials and the anticipated highest risk period.
Abbreviations: HSCT, hematopoietic stem-cell transplantation; IA, invasive aspergillosis; IFD, invasive fungal disease.
4 © 2020 by American Society of Clinical Oncology
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disagreement occurred, it was resolved by consensus or
with arbitration by a third reviewer (T.L. or L.S.). Agreement
in study inclusion was described using the kappa statistic.16
Statistical Analysis
Data synthesis used the risk ratio (RR) with the 95% CI to
describe prophylaxis effects. In this analysis, RR , 1 in-
dicates that the intervention is better than control. The
Mantel-Haenszel random effects model in Review Manager
5.3 (Cochrane Collaboration, Nordic Cochrane Centre,
London, United Kingdom)17was used to estimate treatment
effects. Outcomes were synthesized where there were at
least three studies for main analysis and where there were
at least two studies for each stratum in stratified analysis. If
the number of events was zero in both groups, that study
was not included in synthesis, which is considered
a standard approach in meta-analyses.15 If a study in-
cluded more than two randomized groups, the control
group weight was proportionately divided between the
different intervention groups, and all intervention versus
control comparisons were included in the meta-analysis.15
We also calculated the I2 value, which is the percentage of
total variation across studies as a result of heterogeneity
rather than chance.15
Stratified analysis focused on two comparisons and four
outcomes to limit multiple testing. The two comparisons
were systemic antifungal prophylaxis versus no systemic
antifungal prophylaxis, and mold-active agent versus flu-
conazole. The four outcomes were proven or probable IFD,
proven or probable mold infection, fungal infection–related
mortality, and antifungal discontinuation as a result of
adverse effect (only for mold-active agent v fluconazole
comparison). Strata evaluated were study-level covariates
and, in addition, the risk for IFD and mold in the control
group (above and below the median value). P value for
interaction (P int) was used to determine whether het-
erogeneity in the prophylaxis effect could be explained by
study-level covariates; we did not focus on stratum-specific
P values.15
Funnel plots were used to explore the possibility of publi-
cation bias when at least 10 studies were available for an
analysis.15 Funnel plots are graphical displays of the effect
measure on the x-axis and precision on the y-axis. An
absence of studies in the right lower quadrant (for this
specific analysis) may indicate publication bias. If there was
a suggestion of publication bias, we used the trim and fill
technique to describe its potential impact. In this event,
we removed outlying studies (trim) and added hypothetical
negative studies with equal weight (fill).15 Analysis used
Review Manager 5.3.17
Formulating Recommendations, Assigning Quality of
Evidence, and Manuscript Preparation
We drafted evidence tables based on the systematic review
results. Recommendations were developed during a series
of conference calls and an in-person meeting held in Lyon,
France, on October 25, 2019. Deliberations also used the
results of a recently published systematic review of risk
factors for IFD.4 Draft versions of the recommendations and
manuscript were circulated until approved by all authors.
We used the peer-review mechanism as an efficient ap-
proach to external review. We plan to update this CPG in
5 years or sooner in the event of important new information.
RESULTS
The search strategy identified 68 randomized trials that were
included in the systematic review. Agreement in study in-
clusion between reviewers was perfect (k 5 1.00). The Data
Supplement illustrates the flow diagram of study identifica-
tion, selection, and reasons for exclusion. Health questions,
recommendations, strength of recommendation, level of
evidence, and remarks are summarized in Table 1. Char-
acteristics of the included trials are listed in Table 2, and
study-level details are provided in the Data Supplement.
Among the five trials of voriconazole and six trials of pos-
aconazole, none used therapeutic drug monitoring to sys-
tematically guide dosing. Six studies were conducted solely
in a pediatric population (Data Supplement).
Table 3 provides comparisons between systemic antifungal
prophylaxis versus no systemic antifungal prophylaxis for all
studies and stratified by mold-active agent and non–mold-
active agent (fluconazole). The Data Supplement further
stratifies these analyses by agent evaluated, namely
amphotericin (all formulations), lipid amphotericin formu-
lations, and itraconazole. Compared with no systemic
prophylaxis, systemic antifungal prophylaxis significantly
reduced proven or probable IFD (RR, 0.47; 95% CI, 0.36
to 0.60; P , .00001), proven or probable yeast infection
(RR, 0.31; 95% CI, 0.22 to 0.44; P , .00001), and fungal
infection–related mortality (RR, 0.57; 95% CI, 0.40 to 0.81;
P5 .002). The effects of mold-active agent and non–mold-
active agent versus no systemic antifungal prophylaxis were
similar to the overall analysis for the reduction of IFD, yeast
infection, and fungal infection–related mortality. The Data
Supplement shows stratified analyses of comparisons be-
tween systemic antifungal prophylaxis versus no systemic
prophylaxis for the outcomes of proven or probable IFD,
proven or probable mold infection, and fungal infection–
related mortality. For the outcome of proven or probable
IFD, significantly greater benefit was observed with in-
creasing risk for IFD in the control group, both when the
risk was dichotomized (P int 5 .03; Data Supplement)
and when the risk was divided into quartiles (P int5 .0009;
Data Supplement). More specifically, the effect of pro-
phylaxis was an RR of 0.72 (95% CI, 0.43 to 1.20) for those
in the lowest quartile (smallest risk for IFD) compared with
an RR of 0.25 (95% CI, 0.17 to 0.36) for those in the
highest quartile (greatest risk for IFD). Benefit was also
significantly greater in patients receiving HSCT only com-
pared with chemotherapy only or chemotherapy plus HSCT
(P int 5 .03). The effect of prophylaxis did not differ based
Journal of Clinical Oncology 5
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on risk for mold infection in the control group (P int5 .90).
We also performed an analysis of amphotericin (conven-
tional or lipid formulations) versus no systemic antifungal
prophylaxis stratified by daily dosing versus nondaily
dosing. Effects on IFD and fungal infection–related mor-
tality were similar when comparing daily and nondaily
dosing (Data Supplement).
Table 4 summarizes the comparisons of different systemic
antifungal prophylaxis groups, with additional comparisons
by subcategory and agents shown in the Data Supplement.
Use of a mold-active agent (amphotericin [conventional
or lipid formulations], echinocandin, or mold-active azole),
when compared with fluconazole, significantly reduced
proven or probable IFD (RR, 0.61; 95% CI, 0.49 to 0.76;
P, .00001), proven or probable mold infection (RR, 0.56;
95% CI, 0.42 to 0.74; P , .0001), proven or probable IA
(RR, 0.44; 95% CI, 0.30 to 0.65; P , .0001), and fungal
infection–related mortality (RR, 0.64; 95% CI, 0.45 to 0.91;
P 5 .01). However, use of a mold-active agent significantly
increased discontinuation of antifungal prophylaxis as
a result of an adverse effect (RR, 1.72; 95% CI, 1.09 to
2.71; P 5 .02). When stratified by type of antifungal,
amphotericin (conventional or lipid formulations) did not
reduce proven or probable IFD (RR, 0.99; 95% CI, 0.52 to
1.88; P 5 .98) but did significantly increase discontin-
uation of antifungal prophylaxis as a result of an adverse
effect (RR, 5.63; 95% CI, 1.17 to 27.02; P 5 .03). In
contrast, the benefits of echinocandin versus fluconazole
and mold-active azole versus fluconazole in reducing
proven or probable IFD, proven or probable mold in-
fection, and proven or probable IA were similar to the
overall comparison of mold-active agent versus fluco-
nazole. Table 4 also shows that mold-active azole, when
compared with echinocandin, did not have a statistically
significant different effect on IFD, mold infection, IA, or
yeast infection, but did significantly increase discontin-
uation of antifungal prophylaxis as a result of an adverse
effect. The Data Supplement shows stratified analyses of
TABLE 2. Characteristics of Studies Included in the Systematic Review
Characteristic and Stratum No. of Studies (N 5 68; %)a
Study population characteristics
Treatment
Chemotherapy only 25 (37)
Hematopoietic stem-cell transplantation only 25 (37)
Both chemotherapy and stem-cell transplantation 18 (26)
Age of participants
Adult 41 (60)
Pediatric 6 (9)
Both 20 (29)
Not stated 1 (1)
Interventions included in synthesis
Any systemic antifungal v no systemic antifungal prophylaxisb 27 (40)
Mold-active agent v no systemic antifungal prophylaxisb 14 (21)
Non–mold-active agent (fluconazole) v no systemic antifungal prophylaxisb 13 (19)
Mold-active agent (amphotericin, echinocandin, or mold-active azole) v fluconazole 21 (31)
Amphotericin (conventional or lipid) v fluconazole 4 (6)
Echinocandin (caspofungin or micafungin) v fluconazole 4 (6)
Mold-active azole (itraconazole, posaconazole, or voriconazole) v fluconazole 13 (19)
Mold-active azole v echinocandin 3 (4)
Risk of bias
Adequate sequence generation 30 (44)
Adequate allocation concealment 12 (18)
Participants and personnel blinded 10 (15)
Outcome assessors blinded 12 (18)
Lack of attrition bias 64 (94)
Free of selective reporting 61 (90)
aPercentages may not add to 100% as a result of rounding.
bNo systemic antifungal prophylaxis consists of placebo, no treatment, or nonsystemic antifungals.
6 © 2020 by American Society of Clinical Oncology
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mold-active agent versus fluconazole; no significant in-
teractions were observed.
The Data Supplement shows systemic antifungal pro-
phylaxis initiation and discontinuation criteria by diagnosis
or treatment group and also illustrates sensitivity analyses
where publication bias was suggested in funnel plots. None
substantially altered interpretation of the base analyses. In
addition, the Data Supplement shows synthesis in which
possible IFD, mold, or IA was reported. These did not
substantially alter interpretation of the base analysis. Re-
search gaps are outlined in Table 5.
Recommendation 1
Administer systemic antifungal prophylaxis to children and
adolescents receiving treatment of acute myeloid leukemia
that is expected to result in profound and prolonged neu-
tropenia (Evidence quality: high; Strength of recommenda-
tion: strong).
Explanation. This recommendation was informed by the
systematic review of risk factors identifying that patients
with acute myeloid leukemia are at high risk for IFD. The
benefit of systemic antifungal prophylaxis was greater for
those at higher risk for proven or probable IFD, leading to
this strong recommendation.
Recommendation 2
Consider administering systemic antifungal prophylaxis to
children and adolescents with newly diagnosed and re-
lapsed acute lymphoblastic leukemia at high risk for IFD
(Evidence quality: low; Strength of recommendation: weak).
Explanation. The risk for IFD in pediatric acute lympho-
blastic leukemia is protocol and phase specific. This risk
is also dependent on remission status; chemotherapy-
related neutropenia; and corticosteroid formulation, dose,
and duration of administration. On the basis of the sys-
tematic review of risk factors for IFD,4 the panel believed
that there are likely to be subgroups of pediatric patients
with acute lymphoblastic leukemia who would benefit
from systemic antifungal prophylaxis. However, the panel
was unable to identify comprehensive baseline data
on IFD incidence in the various acute lymphoblastic
leukemia populations that would permit more specific
recommendations. The panel also acknowledged that
treatments for poor-risk acute lymphoblastic leukemia are
changing. For example, immunotherapies are being used
increasingly and may be associated with a lower risk
for IFD compared with conventional, myelosuppressive
chemotherapy. Given these factors, the panel did not
TABLE 3. Systemic Antifungal Prophylaxis Versus No Systemic Antifungal Prophylaxis
Comparison and Outcome No. of Studies RR 95% CI I2 (%) P
Any systemic antifungal v no systemic antifungal prophylaxisa
Proven or probable IFD 27 0.47 0.36 to 0.60 15 , .00001
Proven or probable mold infection 24 0.80 0.48 to 1.33 21 .39
Proven or probable IA 24 0.87 0.50 to 1.52 21 .63
Proven or probable yeast infection 24 0.31 0.22 to 0.44 0 , .00001
Overall mortality 25 0.85 0.73 to 1.00 10 .05
Fungal infection–related mortality 19 0.57 0.40 to 0.81 0 .002
Mold-active agent (amphotericin [conventional or lipid], echinocandin,
or mold-active azole) v no systemic antifungal prophylaxis
Proven or probable IFD 14 0.50 0.35 to 0.72 8 .0002
Proven or probable mold infection 12 0.52 0.22 to 1.26 34 .15
Proven or probable IA 12 0.60 0.23 to 1.55 39 .29
Proven or probable yeast infection 12 0.37 0.21 to 0.65 0 .0007
Overall mortality 14 0.86 0.69 to 1.08 0 .19
Fungal infection–related mortality 11 0.64 0.38 to 1.10 0 .11
Non–mold-active agent (fluconazole) v no systemic prophylaxis
Proven or probable IFD 13 0.44 0.31 to 0.63 26 , .00001
Proven or probable mold infection 12 1.13 0.63 to 2.04 0 .68
Proven or probable IA 12 1.28 0.66 to 2.49 0 .47
Proven or probable yeast infection 12 0.28 0.18 to 0.44 0 , .00001
Overall mortality 11 0.84 0.65 to 1.07 29 .16
Fungal infection–related mortality 8 0.50 0.29 to 0.86 9 .01
Abbreviations: IA, invasive aspergillosis; IFD, invasive fungal disease; RR, risk ratio.
aNo systemic antifungal prophylaxis consists of placebo, no treatment, or nonsystemic antifungals.
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make a strong recommendation for antifungal prophylaxis
in pediatric patients with acute lymphoblastic leukemia.
Rather, the panel made a weak recommendation with the
understanding that protocol-specific recommendations
adjusted to specific phases of therapy such as induction or
reinduction are required.
TABLE 4. Comparison of Different Systemic Antifungal Prophylaxis Agents
Comparison and Outcome No. of Studies RR 95% CI I2 (%) P
Mold-active agent (amphotericin [conventional or lipid], echinocandin
or mold-active azole) v fluconazole
Proven or probable IFD 21 0.61 0.49 to 0.76 0 , .00001
Proven or probable mold infection 19 0.56 0.42 to 0.74 0 , .0001
Proven or probable IA 18 0.44 0.30 to 0.65 0 , .0001
Proven or probable yeast infection 17 1.10 0.71 to 1.70 0 .68
Overall mortality 16 1.01 0.88 to 1.17 0 .87
Fungal infection–related mortality 14 0.64 0.45 to 0.91 0 .01
Discontinuation of antifungal as a result of AE 18 1.72 1.09 to 2.71 79 .02
Amphotericin (conventional or lipid) v fluconazole
Proven or probable IFD 4 0.99 0.52 to 1.88 0 .98
Proven or probable mold infection 3a
Proven or probable IA 4 1.18 0.28 to 4.97 0 .82
Proven or probable yeast infection 3a
Overall mortality 4 1.16 0.81 to 1.67 0 .41
Fungal infection–related mortality 3 0.91 0.39 to 2.16 0 .83
Discontinuation of antifungal as a result of AE 4 5.63 1.17 to 27.02 57 .03
Echinocandin (caspofungin or micafungin) v fluconazole
Proven or probable IFD 4 0.61 0.36 to 1.03 0 .06
Proven or probable mold infection 4 0.59 0.31 to 1.09 0 .09
Proven or probable IA 3 0.17 0.04 to 0.66 0 .01
Proven or probable yeast infection 3 1.08 0.31 to 3.76 18 .91
Overall mortality 4 0.77 0.51 to 1.17 0 .22
Fungal infection–related mortality 3 0.49 0.14 to 1.73 0 .27
Discontinuation of antifungal as a result of AE 4a
Mold-active azole (itraconazole, voriconazole, or posaconazole) v fluconazole
Proven or probable IFD 13 0.56 0.42 to 0.75 11 , .0001
Proven or probable mold infection 12 0.55 0.40 to 0.75 0 .0002
Proven or probable IA 11 0.45 0.29 to 0.70 10 .0004
Proven or probable yeast infection 11 0.85 0.48 to 1.53 0 .59
Overall mortality 8 1.02 0.84 to 1.23 15 .88
Fungal infection–related mortality 8 0.62 0.37 to 1.04 32 .07
Discontinuation of antifungal as a result of AE 10 1.73 1.04 to 2.88 82 .04
Mold-active azole v echinocandin
Proven or probable IFD 3 0.73 0.32 to 1.65 0 .45
Proven or probable mold infection 3 0.74 0.21 to 2.62 0 .65
Proven or probable IA 3 0.88 0.24 to 3.21 0 .85
Proven or probable yeast infection 3 0.83 0.30 to 2.27 0 .71
Overall mortality 3 0.83 0.28 to 2.46 29 .73
Discontinuation of antifungal as a result of AE 3 11.04 1.28 to 95.40 74 .03
Abbreviations: AE, adverse effects; IA, invasive aspergillosis; IFD, invasive fungal disease; RR, risk ratio.
aNo synthesis possible because there were less than three studies with an event in at least one arm.
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Recommendation 3
Do not routinely administer systemic antifungal prophylaxis
to children and adolescents with acute lymphoblastic
leukemia at low risk for IFD (Evidence quality: low; Strength
of recommendation: strong).
Explanation. For children and adolescents with acute
lymphoblastic leukemia, a low risk for IFD can be inferred
based on absence of risk factors such as prolonged neu-
tropenia and corticosteroid administration, combined with
observed IFD rates across different protocols and phases
of therapy. This group includes, for example, pediatric
patients receiving maintenance chemotherapy for acute
lymphoblastic leukemia.
Recommendation 4
Do not routinely administer systemic antifungal prophylaxis
to children and adolescents with cancer at low risk for IFD,
such as most pediatric patients with lymphomas and solid
tumors (Evidence quality: moderate; Strength of recom-
mendation: strong).
Explanation. In pediatric patients at low risk for IFD, benefit
of systemic antifungal prophylaxis is likely to be small and
outweighed by the risk for adverse effects, costs, and in-
convenience. Thus, systemic antifungal prophylaxis should
not routinely be administered in this setting. It is important
to emphasize that some patients with lymphomas and solid
tumors are at high risk for IFD, such as those with advanced
Burkitt lymphoma and some infants with brain tumors.
Thus, implementationmust consider patient- and treatment-
specific risk factors rather than relying on diagnosis
alone in deciding which populations merit antifungal
prophylaxis.
Recommendation 5
Administer systemic antifungal prophylaxis to children and
adolescents undergoing allogeneic HSCT pre-engraftment
and to those receiving systemic immunosuppression for the
treatment of graft-versus-host disease (GVHD; Evidence
quality: moderate; Strength of recommendation: strong).
Explanation. The panel recognized that pre-engraftment
and during systemic immunosuppression for the treat-
ment of GVHD were two distinct periods, each increasing
the risk for IFD but with different epidemiology. The Data
Supplement shows that many studies of allogeneic HSCT
recipients included both periods, with few studies focusing
on the period of immunosuppression for GVHD treatment.
Thus, the panel felt this lack of granularity precluded
separate recommendations for these two different periods.
This strong recommendation was influenced by the finding
in the systemic prophylaxis versus no systemic prophylaxis
stratified analysis that HSCT recipients experienced greater
benefit in proven or probable IFD reduction compared with
chemotherapy recipients (Data Supplement). In addition,
the subgroup analysis showed that among the HSCT stra-
tum, antifungal prophylaxis significantly reduced fungal
infection–related mortality (Data Supplement). Although the
adult data were clearer, these data may be less generalizable
to pediatric patients because of different transplantation
approaches such as stem-cell source. As a result, the evi-
dence quality was reduced. The panel suggested that ad-
ministration in patients receiving systemic treatment of
GVHDwas reasonable based on risk factors for IFD but could
not provide more granularity around whether there is
a subgroup in which GVHD treatment is sufficiently short as
to not warrant antifungal prophylaxis.
TABLE 5. Key Knowledge Gaps Related to Systemic Antifungal Prophylaxis Among Children and Adolescents With Cancer and Pediatric Hematopoietic
Stem-Cell Transplantation Recipients
Knowledge Gap
Identifying personalized risk factors for IFD, allowing for more targeted prophylaxis among patients at highest risk for IFD
Describing the risk for IFD with recently developed modalities of cancer therapy including immunotherapy
Determining whether fluconazole prophylaxis combined with sensitive diagnostic tests and procedures to detect IFD is as effective as prophylaxis with
mold-active agents
Describing the risks and benefits of lipid formulations of amphotericin prophylaxis compared with other mold-active agent prophylaxis
Identifying optimal systemic antifungal prophylaxis for infants and neonates
Determining ideal dosing and scheduling of systemic antifungal prophylaxis agents
Determining whether therapeutic drug monitoring has a role in guiding mold-active azole dosing when administered for prophylaxis
In an era of mold-active prophylaxis, evaluating the comparative effectiveness of different diagnostic and therapeutic antifungal approaches including
preemptive and empirical treatment
Determining how to best develop and implement a fungal surveillance program
Evaluating antifungal resistance after implementation of different prophylactic antifungal strategies
Understanding how to adapt this clinical practice guideline for low- and middle-income country settings
Understanding the contribution of environmental interventions such as high-efficiency particulate air filtration to the prevention of IFD
Assessing clinical practice guideline concordance in routine clinical care and impact of concordant v nonconcordant practices
Abbreviation: IFD, invasive fungal disease.
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Recommendation 6
We suggest that systemic antifungal prophylaxis not be
used routinely in children and adolescents undergoing
autologous HSCT (Evidence quality: low; Strength of rec-
ommendation: weak).
Explanation. A lower risk for IFD associated with autolo-
gous HSCT can be inferred from the systematic review of
IFD risk factors.4 Consequently, systemic antifungal pro-
phylaxis was not recommended for this group. However,
there was less certainty in the setting of tandem trans-
plantations where the cumulative duration of neutropenia
may be longer. The degree of mucositis associated with
specific conditioning regimens may also influence IFD risk
and may affect the decision to administer antifungal
prophylaxis.
Recommendation 7
If systemic antifungal prophylaxis is warranted, administer
a mold-active agent (Evidence quality: high; Strength of
recommendation: strong).
Explanation. This strong recommendation was based on
the comparison of different systemic antifungal prophylaxis
agents (Table 4) where a mold-active agent versus fluco-
nazole significantly reduced proven or probable IFD, mold
infection, and IA, and reduced fungal infection–related
mortality. Although a mold-active agent also increased
adverse effects, the panel felt the benefits outweighed the
negative aspects. Direct pediatric data were available, in-
creasing quality of the evidence.
Trials comparing a mold-active agent versus fluconazole
were presumably conducted in settings where there is an
appreciable risk for mold infection. In settings where the
risk for mold is sufficiently low, fluconazole may be an
appropriate choice for prophylaxis.
Recommendation 8
In choosing a mold-active agent, administer an echino-
candin or a mold-active azole (Evidence quality: moderate;
Strength of recommendation: strong).
Explanation. If systemic antifungal prophylaxis is war-
ranted, the choice of which specific mold-active agent is
influenced by multiple factors including local epidemiology,
adverse effect profile, drug interaction potential, costs,
and jurisdictional availability. All mold-active agents have
disadvantages. For example, echinocandins must be ad-
ministered intravenously daily, which may make this option
less desirable for ambulatory populations. Use of mold-
active azoles may be limited by drug interactions, hepa-
totoxicity, and adverse effects resulting in discontinuation of
prophylaxis. For children younger than 13 years of age, an
echinocandin, voriconazole, or itraconazole is suggested
based on efficacy, adverse effects, and availability of pe-
diatric dosing information. In settings where all agents are
available, either an echinocandin or voriconazole is favored
based on toxicity profile. However, itraconazole may be
used if other options are not available. Posaconazole may
also be used in those 13 years of age and older. When using
mold-active azoles, best practices with respect to thera-
peutic drug monitoring should be applied.
Recommendation 9
Do not use amphotericin routinely as systemic antifungal
prophylaxis (Evidence quality: low; Strength of recom-
mendation: strong).
Explanation. This strong recommendation was based on
the finding that amphotericin was not more effective than
fluconazole in reducing proven or probable IFD but was
associated with more adverse effects (Table 4). Stratified
analysis did not reveal differential efficacy based on
whether amphotericin was administered on a daily or
nondaily schedule (Data Supplement).
Recommendation 10
If systemic antifungal prophylaxis is warranted, consider
administration during periods of observed or expected
severe neutropenia. For allogeneic HSCT recipients, con-
sider administration during systemic immunosuppression
for GVHD treatment (Evidence quality: low; Strength of
recommendation: weak).
Explanation. There are limited data that inform the decision
of when to initiate and discontinue systemic antifungal
prophylaxis. This recommendation was based both on
criteria used in the included randomized trials and the
anticipated highest risk periods.
DISCUSSION
This CPG of systemic antifungal prophylaxis is important
because of the impact of IFD in pediatric patients with
cancer and HSCT recipients and uncertainty in the ideal
approach. If systemic antifungal prophylaxis is warranted,
the panel made a strong recommendation to administer
a mold-active agent with an echinocandin or a mold-active
azole. In choosing a specific agent, local epidemiology,
adverse effect profile, potential for drug interactions, costs,
and jurisdictional availability must be weighed against each
other for specific settings. If all agents are available and
appropriate from a microbiologic perspective, echino-
candins may be favored when limiting adverse effects and
hepatotoxicity are valued. Conversely, mold-active azoles
may be favored when oral administration and convenience
are favored.
It is possible that more broad-spectrum antifungal pro-
phylaxis will change the choice of empirical antifungal
therapy, and if the new choice has more adverse effects,
the strategy could result in more toxicity overall. Future
comparative effectiveness studies should evaluate the
overall impact of antifungal prophylaxis selection on em-
pirical antifungal choice and overall toxicities.
We found that fluconazole, when compared with no systemic
antifungal prophylaxis, was associated with a reduction in
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fungal infection–related mortality but not overall mortality. It
is possible that the reduction in fungal infection–related
mortality occurred because these trials were conducted at
a time when there were fewer IFD treatment options. It is also
possible that this reduction is related to classification bias
given the challenges in assigning cause of death.5
As with all CPGs, a structured approach to local adaptation,
implementation, and evaluation is a key consideration.
Important factors in this process include a baseline un-
derstanding of local and disease-specific epidemiology,
establishing a leadership team that will oversee the pro-
cess, and appropriate engagement and education of key
stakeholders. Pediatric acute lymphoblastic leukemia is
a particularly challenging population in which to make
universal recommendations regarding systemic antifungal
prophylaxis because of the wide variability in treatment
regimens, each with differing IFD risk patterns and limi-
tations to specific antifungal agents. Implementation of this
CPG will likely require protocol-specific recommendations
for patients with acute lymphoblastic leukemia.
In summary, we created a CPG for systemic antifungal
prophylaxis in pediatric patients with cancer and HSCT
recipients. Implementation and assessment of guideline-
concordant rates and impacts are important future steps.
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